Arabic Arabic English English French French German German
dark

Biocon Downplays Mysterious CRL for Insulin Biosimilar

​While Biocon intends to address the CRL, the company has not established a timeline for the resubmission of data and hopes that the FDA will rapidly review the BLA when it does submit the data. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Sanofi, Exscientia Expand in AI with Up-to-$5.2B Cancer, Immunology Alliance

Next Post

Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More Patients

Related Posts
Total
0
Share